Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon

被引：0
|
作者：
Schuette, W. [1 ]
Thomas, M. [2 ]
Eberhardt, W. [3 ]
Zirrgiebel, U. [4 ]
Radke, S. [5 ]
Dietel, M. [6 ]
机构：
[1] Krankenhaus Martha Maria, Halle, Saale, Germany
[2] Univ Klinikum, Thoraxklin, Heidelberg, Germany
[3] Univ Klinikum, Med Onkol, Essen, Germany
[4] iOMEDICO AG, Freiburg, Germany
[5] AstraZeneca GmbH, Wedel, Germany
[6] Humboldt Univ, Pathol Inst, D-10099 Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0341
引用
收藏
页码：120 / 120
页数：1
相关论文
共 41 条
  • [31] Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
    Montagut, C.
    Alonso, V.
    Escudero, P.
    Fernandez-Martos, C.
    Salud Salvia, A.
    Mendez, M.
    Gallego Plazas, J.
    Rodriguez, J. R.
    Martin-Richard, M.
    Fernandez-Plana, J.
    Aparicio, J.
    Feliu Batlle, J.
    Garcia de Albeniz, X.
    Rojo, F.
    Fernandez, V.
    Claes, B.
    Maertens, G. G.
    Sablon, E.
    Jacobs, B. A. W.
    Maurel, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hoehler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Ting, Saskia
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kosbade, Karina
    Worm, Karl
    Schmid, Kurt Werner
    Herold, Thomas
    Schuler, Martin H.
    Trarbach, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Impact of EGFR mutation status on clinical outcome of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer (NSCLC): Retrospective analysis of Korean nintedanib named-patient usage (NPU) program in NSCLC (KCSG LU14-2)
    Hong, Sook-hee
    An, Ho Jung
    Lee, Yun-Gyoo
    Kim, Hoon-Kyo
    Lee, Seung-Sei
    Kang, Jin Hyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Does targeted therapy dominate in terms of a higher level of effectiveness for a given cost compared to wild-type treatment? An analysis of cost and outcome of metastatic lung cancer patients in Saudi Arabia.
    Da'ar, Omar B.
    Alkhybri, Ali
    Alshareed, Saud
    Alkaiyat, Mohammad
    Jazieh, Abdul Rahman
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial
    Qu, Aidong
    Zhang, Shiying
    Zou, Hongxia
    Li, Sixiu
    Chen, Dandan
    Zhang, Yaowen
    Li, Songsong
    Zhang, Huijun
    Yang, Ji
    Yang, Yunkai
    Huang, Yubao
    Li, Xiuling
    Zhang, Yuntao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 12713 - 12721
  • [36] Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial
    Aidong Qu
    Shiying Zhang
    Hongxia Zou
    Sixiu Li
    Dandan Chen
    Yaowen Zhang
    Songsong Li
    Huijun Zhang
    Ji Yang
    Yunkai Yang
    Yubao Huang
    Xiuling Li
    Yuntao Zhang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 12713 - 12721
  • [37] Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
    Raimondi, Alessandra
    Nichetti, Federico
    Stahler, Arndt
    Wasan, Harpreet S.
    Aranda, Enrique
    Randon, Giovanni
    Kurreck, Annika
    Meade, Angela M.
    Diaz-Rubio, Eduardo
    Niger, Monica
    Stintzing, Sebastian
    Palermo, Federica
    Trarbach, Tanja
    Prisciandaro, Michele
    Sommerhauser, Greta
    Fisher, David
    Morano, Federica
    Pietrantonio, Filippo
    Modest, Dominik P.
    EUROPEAN JOURNAL OF CANCER, 2023, 190
  • [38] Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M plus ) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials
    Schuler, M.
    Sequist, L. V.
    Yang, J. C.
    Yamamoto, N.
    O'Byrne, K. J.
    Mok, T.
    Geater, S. L.
    Massey, D.
    Wind, S.
    O'Brien, D.
    Lorence, R.
    Wu, Y. -L.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 90 - 90
  • [39] EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese (JPN) patients (pts) with metastatic colorectal cancer (mCRC) harboring overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) treated with cetuximab (cet) plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR).
    Sunakawa, Yu
    Ichikawa, Wataru
    Tsuji, Akihito
    Moran, Miriana
    Astrow, Stephanie H.
    Yang, Dongyun
    Zhang, Wu
    Takahashi, Takehiro
    Denda, Tadamichi
    Shimada, Ken
    Kochi, Mitsugu
    Nakamura, Masato
    Kotaka, Masahito
    Segawa, Yoshihiko
    Takeuchi, Masahiro
    Lenz, Heinz-Josef
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [40] Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) - Primary endpoint and subgroup analysis of the CEBIFOX trial
    Kasper, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, H. T.
    Berger, W.
    Linden, G.
    Ting, S.
    Markus, P.
    Paul, A.
    Dechene, A.
    Schumacher, B.
    Kostbade, K.
    Worm, K.
    Schmid, K. W.
    Herold, T.
    Schuler, M.
    Trarbach, T.
    ANNALS OF ONCOLOGY, 2016, 27
12345